Publicacións en colaboración con investigadores/as de Harvard Medical School (3)

2022

  1. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

    Circulation, Vol. 146, Núm. 16, pp. 1196-1206

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

2017

  1. Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: Insights from the five-year follow-up of the EXAMINATION trial

    EuroIntervention, Vol. 13, Núm. 5, pp. e557-e563